Direct Long R3 IGF-1 literature is largely about recombinant production and animal biology. Some endpoints changed, while a 739-oocyte comparison found no difference in meiotic progression or apoptosis.
Evidence at a glance
- A 2023 Pichia study reported about 1 g/L for a xylanase-TEV-LR3 IGF-1 fusion in a 15 L bioreactor.
- A 2020 study analyzed 739 bovine cumulus-oocyte complexes in 10 pools and found no group difference in meiotic progression or apoptosis.
- A 1999 heifer study reported tendencies toward protein conservation and marked reductions in plasma amino acids and glucose, not human anabolic efficacy.
Study record
The 2023 paper used xylanase as a fusion partner to raise heterologous expression in Pichia pastoris. Purified IGF-1 and LR3 IGF-1 showed cell-proliferation activity comparable with a standard, but production yield and an in-vitro bioassay do not establish clinical effect.
Results in context
In bovine oocyte maturation, 100 ng/mL IGF-1 or Long R3 IGF-1 was compared with PVA and fetal-bovine-serum controls. Some gene-expression differences were reported, but meiotic progression and apoptosis did not differ. Preserving that null result prevents selective reporting.
In restricted-fed beef heifers, an eight-hour infusion tended to preserve whole-body and muscle protein and changed circulating metabolites and binding proteins. Species, nutritional state and infusion design make the findings unsuitable for direct human performance claims.
What the evidence cannot establish
Fusion-protein yield is a manufacturing result, not an efficacy outcome.
Cattle cell and whole-animal findings require human pharmacology and safety studies before translation.
The direct literature is too heterogeneous to support a single universal mechanism or benefit claim.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits and regulatory scope are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Recombinant expression of IGF-1 and LR3 IGF-1 in Pichia pastorisBiotechnology study. 2023. PMID 37261455.
- IGF-1 and LongR3 IGF-1 in bovine oocyte maturationComparative 739-COC study with null meiotic/apoptosis results; PMID 33038561.
- Action of long(R3)-IGF-1 on protein metabolism in beef heifersAnimal study. 1999. PMID 10370861.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
